ALSAF Safe Orthopaedics SAS

Half-year report on the liquidity contract between Safe Orthopaedics and Louis Capital Markets

Half-year report on the liquidity contract between Safe Orthopaedics and Louis Capital Markets

Eragny-sur-Oise, France, January 12th, 2021 - 18h00 CEST – Safe Orthopaedics (FR0013467123 - ALSAF), a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated, is today releasing its half-year report on the liquidity contract signed with Louis Capital Markets.

Under the contract, the liquidity account had the following holdings as of December 31st, 2020:

  • 584 shares
  • -35,87 euros

During the first half of 2020, the following have been negotiated:



PURCHASE 4,582 shares 1,803.84 euros 513 transactions
SALE 5,010 shares 1,947.17 euros 503 transactions

 

For the prior period (June 30th, 2020), the corresponding figures were:

  • 1 012 shares
  • 364,57 euros

As of March 18, 2019 (implementation of the new liquidity contract), the followings were made available:

  • 74 738 shares
  • 7 561,33 euros

Following the acquisition of Louis Capital Market|Midcap Partners by the group TPICAP Plc, the liquidity contract previously owned by Louis Capital Markets UK, LLP has been automatically transferred on 31/12/2020 to TP ICAP (EUROPE), the French entity of the group TPICAP, authorized and regulated by the French Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).

The detail of day-to-day activities is as follows:

  Purchase Sale
ALSAF FP Trading volume Number of shares Cash (EUR) Trading volume Number of shares Cash (EUR)
Total 513 4 582 1 803,84 503 5 010 1 947,17
20200701 4 59 29,32 1 1 0,50
20200702 3 38 18,60 6 101 51,73
20200703 5 75 36,77 5 60 31,07
20200706 1 1 0,52 9 158 82,22
20200707 4 71 35,64 5 62 32,71
20200708 4 57 28,40 2 21 10,75
20200709 4 56 27,30 1 1 0,49
20200710 5 65 30,90 1 1 0,48
20200713 2 14 6,45 5 71 33,60
20200714 3 35 16,15 4 56 26,75
20200715 4 55 25,63 1 1 0,48
20200716 2 15 6,90 4 56 26,41
20200717 1 1 0,48 5 67 32,33
20200720 5 75 35,28 2 12 5,82
20200721 3 38 18,30 1 1 0,49
20200722 1 1 0,49 6 119 59,14
20200723 5 58 28,61 2 21 10,67
20200724 4 32 15,39 1 1 0,49
20200727 3 22 10,49 11 202 105,98
20200728 4 51 24,87 5 57 28,71
20200729 4 51 24,84 2 2 1,00
20200730 4 46 22,17 4 50 24,93
20200731 4 39 18,42 1 1 0,47
20200803 3 24 11,50 2 21 10,29
20200804 4 18 8,48 4 56 27,10
20200805 5 22 10,26 2 21 10,11
20200806 2 4 1,88 2 221 103,02
20200807 4 25 11,59 2 19 9,01
20200810 5 21 9,67 3 30 14,25
20200811 1 1 0,69 11 145 100,76
20200812 8 57 28,86 2 15 7,95
20200813 7 48 22,87 1 1 0,49
20200814 5 32 14,45 6 78 36,63
20200817 5 37 17,21 2 16 7,65
20200818 4 24 10,95 3 21 9,87
20200819 4 24 10,78 2 9 4,14
20200820 6 41 17,55 1 1 0,45
20200821 4 22 9,22 1 1 0,43
20200824 1 1 0,43 4 44 18,81
20200825 2 5 2,07 2 14 5,88
20200826 3 19 7,84 3 22 9,30
20200827 4 24 9,88 3 22 9,35
20200828 2 10 4,09 4 41 17,23
20200831 4 27 11,03 2 9 3,76
20200901 6 46 17,69 1 1 0,39
20200902 4 23 8,62 1 1 0,38
20200903 1 1 0,38 4 44 16,77
20200904 1 1 0,38 3 22 8,35
20200907 5 38 13,90 5 56 21,47
20200908 3 23 8,61 6 67 26,80
20200909 5 45 16,75 4 36 14,04
20200910 3 26 9,47 6 60 22,71
20200911 4 35 13,11 1 1 0,38
20200914 4 32 11,85 4 36 13,86
20200915 4 32 11,84 1 1 0,37
20200916 1 1 0,37 4 39 14,56
20200917 3 27 10,04 1 1 0,37
20200918 3 21 7,78 1 1 0,38
20200921 4 30 10,94 4 40 15,20
20200922 3 25 8,88 4 39 14,39
20200923 4 32 11,52 3 20 7,39
20200924 4 32 11,37 4 39 14,31
20200925 4 34 11,90 2 8 2,87
20200928 2 9 3,18 6 72 26,55
20200929 4 36 12,65 5 48 18,14
20200930 3 25 8,97 2 10 3,69
20201001 1 1 0,35 2 10 3,55
20201002 6 63 21,69 1 1 0,35
20201005 5 50 16,52 11 125 45,09
20201006 10 92 37,69 5 50 22,08
20201007 3 25 9,55 6 71 28,12
20201008 5 52 20,68 1 1 0,40
20201009 11 100 35,72 1 1 0,36
20201012 7 53 18,56 1 1 0,36
20201013 1 1 0,35 3 31 10,80
20201014 1 1 0,34 1 1 0,34
20201015 4 29 9,77 1 1 0,34
20201016 2 10 3,36 1 1 0,34
20201019 2 10 3,34 3 32 10,89
20201020 6 42 13,84 1 1 0,33
20201021 5 33 10,38 4 53 17,23
20201022 5 37 11,35 1 1 0,32
20201023 7 45 13,31 2 4 1,23
20201026 11 62 17,45 4 54 16,54
20201027 9 49 12,47 2 21 5,66
20201028 10 58 13,41 1 1 0,24
20201029 7 35 7,37 2 21 4,60
20201030 5 25 5,13 10 161 35,23
20201102 1 1 0,23 9 134 30,66
20201103 2 15 3,47 7 90 21,59
20201104 4 47 11,26 5 53 13,10
20201105 10 119 27,56 4 41 10,20
20201106 1 1 0,25 11 135 33,90
20201109 5 66 16,25 4 33 8,59
20201110 5 62 15,00 2 12 3,00
20201111 3 29 6,97 2 15 3,69
20201112 2 19 4,57 4 39 9,64
20201113 2 20 4,83 2 15 3,69
20201116 1 1 0,25 9 94 24,39
20201117 3 32 8,28 5 37 10,01
20201118 6 77 19,84 2 11 2,96
20201119 3 30 7,55 1 1 0,25
20201120 4 43 10,59 4 38 9,75
20201123 1 1 0,26 4 39 10,14
20201124 2 20 5,03 3 30 7,74
20201125 3 32 7,97 3 30 7,72
20201126 3 27 6,72 4 41 10,57
20201127 1 1 0,25 4 33 8,39
20201130 2 21 5,29 2 13 3,34
20201201 1 1 0,26 11 101 27,90
20201202 1 1 0,29 4 25 7,13
20201203 4 53 14,42 5 29 8,67
20201204 3 34 9,24 2 10 2,80
20201207 4 51 13,61 4 27 7,54
20201208 4 55 14,82 4 31 8,62
20201209 5 66 17,37 1 1 0,27
20201210 5 65 16,94 3 24 6,46
20201211 1 1 0,27 1 1 0,27
20201214 1 1 0,27 7 81 21,61
20201215 4 52 13,61 11 103 28,68
20201216 4 58 15,18 9 77 21,66
20201217 1 1 0,28 11 85 24,37
20201218 5 81 22,10 6 40 11,43
20201221 4 58 15,33 11 77 21,63
20201222 1 1 0,35 11 63 22,21
20201223 1 1 0,90 11 44 39,60
20201224 11 74 75,07 6 11 12,20
20201225 0 0 0,00 0 0 0,00
20201228 0 0 0,00 0 0 0,00
20201229 10 136 89,82 0 0 0,00
20201230 9 119 63,52 11 31 18,72
20201231 10 121 81,71 1 1 0,69

  

Next financial release:

Annual 2020 results, January 14th, 2021 (post-market)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company, a pioneer of the design and marketing of innovative ready-to-use technologies (single-use implants and instruments) for spinal fractures treatments. The company develops and manufactures kits combining sterile implants and single-use instruments, available at any time for the surgeon. These technologies enable minimally invasive approach, reducing the risk of cross contamination and infection, in the interest of the patient with a positive impact on hospitalization durations and costs. Protected by 17 patent families, the SteriSpineTM PS are CE marked and FDA approved. Safe Orthopaedics has its headquarters close to Paris (95610 Eragny-sur-Oise - France) has subsidiaries in the UK, Germany, United States and in the Lyon area where the manufacturing company is located. The Group employs around 150 employees.

For more information :





Contacts 

Safe Orthopaedics                                                                                                                 

François-Henri Reynaud                                                             

Chief Financial Officer                  

Tél. : +33 (0)1 34 21 50 00                                        

              

Press Relations

Ulysse Communication

Pierre-Louis Germain / +33 (0)6 64 79 97 61 /

Bruno Arabian / +33 (0)6 87 88 47 26 /

Attachment



EN
12/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Safe Orthopaedics SAS

Arnaud Riverain
  • Arnaud Riverain

SAFE (ALSAFE) / Résultats 2022

Marge brute et résultat opérationnel proches de nos attentes ; Résultat net pénalisé par les pénalités de financement ; Objectif d’équilibre financier d’ici 24 à 36 mois.

 PRESS RELEASE

Distribution agreements signed for the UK

Distribution agreements signed for the UK            Distribution agreements signed for the UK Direct distribution in ScotlandIndirect distribution in England and Wales         Éragny-sur-Oise, Fleurieux-sur-l'Arbresle, May 3rd, 2023 at 8:30 a.m. CET - Safe (FR001400F1V2 - ALSAF), a company specializing in the design, manufacture and marketing of ready-to-use technologies for back surgery, particularly safe for spinal fractures treated in emergency (the "Company") announces strategic sales agreement for the United Kingdom area. Since acquiring its distributor in 2018...

 PRESS RELEASE

Signature d’accords de distribution au Royaume Uni

Signature d’accords de distribution au Royaume Uni            Signature d’accords de distribution au Royaume Uni Distribution directe en EcosseDistribution indirecte en Angleterre et au Pays de Galles       Éragny-sur-Oise, Fleurieux sur l’Arbresle, France, le 03 mai 2023 à 8h30 CET – Safe (FR001400F1V2 – ALSAF), société spécialisée dans la conception, la fabrication et la commercialisation de technologies prêtes-à-l’emploi pour la chirurgie du dos, particulièrement sécurisantes pour les fractures vertébrales traitées en urgence, annonce des accords de ventes stratég...

 PRESS RELEASE

Safe group modifies its financial agenda

Safe group modifies its financial agenda            Safe group modifies its financial agenda             Éragny-sur-Oise, Fleurieux-sur-l'Arbresle, April 26th, 2023 at 8:30 a.m. CET - Safe (ALSAF), a company specializing in the design, manufacture and marketing of ready-to-use technologies for back surgery, particularly safe for spinal fractures treated in emergency (the "Company") announces the modiication of its financial agenda. François-Henri Reynaud, Chief Financial Officer of Safe Group, said: "Due to calendar constraints, we have decided to change the date of ...

 PRESS RELEASE

Safe group modifie son agenda financier

Safe group modifie son agenda financier            Safe group modifie son agenda financier         Éragny-sur-Oise, Fleurieux sur l’Arbresle, France, le 26 avril 2023 à 8h30 CET – Safe (FR001400F1V2 – ALSAF), société spécialisée dans la conception, la fabrication et la commercialisation de technologies prêtes-à-l’emploi pour la chirurgie du dos, particulièrement sécurisantes pour les fractures vertébrales traitées en urgence, annonce aujourd’hui la modification de son agenda financier. François-Henri Reynaud, Directeur Administratif et Financier de Safe group décla...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch